DCPH News and Press, Deciphera Pharmaceuticals Inc. From 08/19/19

Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced registered underwritten public offering. 10,810,810 shares of the Company’s c...

On Wednesday evening, Deciphera Pharmaceuticals, Inc. ( DCPH ) announced a $400 million capital raise consisting of 10,810,810 shares priced at $37.00 with an underwriter option for an additional $60 million worth of shares. This was double the initial proposed offering of $200 million. I ...

Deciphera Pharmaceuticals (NASDAQ: DCPH ) prices its public offering of ~10.8M common shares at $37 per share. Underwriters over-allotment is an additional ~1.6M shares. Closing date is August 19. More news on: Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of its previously announced registered underwritten public offering of 10,810,810 shares of its common stock at ...

August 14, 2019 Palm Beach, FL – August 14, 2019 – People with cellulite are not as happy as those without cellulite. That may seem to be self-evident, but now it is supported by studies. One such report, a study published by Surgical and Cosmetic Dermatology, fo...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the commencement of a registered underwritten public offering of $200.0 million in shares of its common stock. In addition, ...

Gainers:  Mmtec (NASDAQ: MTC ) +346% . Deciphera Pharmaceuticals (NASDAQ: DCPH ) +87% . PEDEVCO (NYSEMKT: PED ) +40% . Mustang Bio (NASDAQ: MBIO ) +24% . OptiNose (NASDAQ: OPTN ) +22% . LSC Communications (NYSE: LKSD ) +21% . Foamix Pharmaceuticals (NASDAQ: FOMX ) +18% . Jumia ...

Deciphera Pharmaceuticals (NASDAQ: DCPH ) +121%  on positive late-stage ripretinib data . More news on: Deciphera Pharmaceuticals, Inc., DelMar Pharmaceuticals, Inc., Alcentra Capital Corporation, Stocks on the move, Read more ...

Thinly traded Deciphera Pharmaceuticals (NASDAQ: DCPH ) is up  101%  premarket on increased volume in reaction to positive topline results from a 129-subject Phase 3 clinical trial, INVICTUS , evaluating ripretinib, a broad-spectrum KIT and PDGFRα inhibitor, in patients w...

- Data from Phase 1 Study Supports Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST – - Median Progression Free Survival (mPFS) Sustained across All Cohorts - - Additional Phase 1 Results Expected to be Presented at Upcoming Medical Meeting - -...